US PTAB Patent Cases
8,722 decisions indexed
Page 76 of 291 · 8,722 total
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Apple’s wearable physiological measurement claims were obvious over prior‑art pulse‑oximetry references, rendering all challenged claims unpatentable. The decision relied on Lisogurski, Carlson, and Mannheimer teachings.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR resulted in the Board finding all six challenged claims of Omni MedSci’s ’299 patent unpatentable as obvious over a combination of prior‑art references covering wearable optical sensing.
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
Samsung Electronics and Radian Memory Systems settled their IPR dispute over patent 11307995 before trial. The Board granted the joint motion to terminate, ending the proceedings.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision in IPR2021‑00453, finding claims 1,2,7 and 15‑23 of Omni MedSci’s wearable pulse‑oximeter patent unpatentable over prior art, while leaving the remaining claims intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable physiological measurement patent resulted in all challenged claims being held unpatentable. The Board found the claims obvious over Lisogurski, Carlson, and Mannheimer under §103(a).
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s inter‑partes review of Omni MedSci’s ’533 patent resulted in the PTAB finding all challenged claims unpatentable for obviousness over Lisogurski, Carlson, and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple won a PTAB IPR against Omni MedSci, finding 12 of the 23 challenged claims of the 10,517,484 B2 wearable health‑monitoring patent unpatentable, while the remaining claims survived.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable health‑monitoring patent resulted in the Board finding all challenged claims unpatentable as obvious over a combination of prior‑art references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple (as petitioner) secured a Final Written Decision finding claims 1,2,7,15‑23 of Omni MedSci’s wearable health‑monitoring patent unpatentable as obvious over prior‑art. The Board affirmed the petitioner's obviousness arguments while leaving claims 3‑6 and 8‑14 intact.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s petition succeeded; the PTAB held all challenged claims of Omni MedSci’s wearable physiological measurement patent unpatentable as obvious over Lisogurski, Carlson, and Mannheimer references.
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
Samsung and Radian Memory Systems settled their IPR dispute over patent 11,347,656 before trial, leading the Board to terminate the proceedings.
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
Samsung and Radian have filed a joint motion to terminate IPR2025-01376 under 35 U.S.C. § 317(a) after reaching a confidential settlement. The Board has not yet issued an institution decision.
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
Samsung Electronics and Radian Memory Systems settled their IPR dispute (IPR2025-01378) before trial. The Board granted the joint motion to terminate and kept the settlement documents confidential.
Samsung Electronics Co., Ltd. et al. v.Radian Memory Systems LLC
Samsung and Radian Memory Systems have reached a confidential settlement and jointly moved to terminate the inter partes review of U.S. Patent 11,347,656. The Board is asked to dismiss the proceeding under 35 U.S.C. § 317(a).
Regions Bank v.United Services Automobile Association
Regions Bank and USAA jointly moved to keep their IPR settlement agreement confidential under 35 U.S.C. § 317(b) and related regulations.
Regions Bank v.United Services Automobile Association
Regions Bank and United Services Automobile Association have settled their dispute over U.S. Patent No. 12,211,095 and jointly moved to terminate the inter partes review. The Board is asked to dismiss the proceeding under §317(a) before any merits are decided.
BOE Technology Group Co., Ltd. v.Paneltouch Technologies LLC
BOE Technology and Paneltouch Technologies settled their inter partes review of U.S. Patent 11,126,025, leading the PTAB to terminate the proceeding and keep the settlement confidential.
BOE Technology Group Co., Ltd. v.Paneltouch Technologies LLC
BOE Technology Group and Paneltouch Technologies have settled the IPR dispute over U.S. Patent 11,126,025. The parties filed a joint motion to seal the settlement agreement as business confidential information, keeping it separate from the IPR record.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision on remand, holding that all 23 claims of Omni MedSci’s wearable pulse‑oximeter patent are unpatentable. The Board relied on an obviousness analysis over a combination of prior‑art references and affirmed the claim construction of “identify an object.”
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB issued a Final Written Decision on Remand, finding all 23 claims of Omni MedSci’s wearable pulse‑oximeter patent unpatentable. Apple’s arguments on obviousness over multiple prior‑art references prevailed.
Apple Inc. v.Telcom Ventures LLC
Apple Inc. filed a motion to dismiss its IPR petition against Telcom Ventures LLC’s ’708 patent, arguing that the Board has not yet decided on institution and that dismissal will conserve resources. The motion references the related district‑court litigation where the patent was dismissed with prejudice.
Regions Bank v.United Services Automobile Association
Regions Bank and USAA settled their inter partes review dispute over USAA’s automobile‑insurance patent. The Board granted a joint motion to terminate the IPRs and kept the settlement agreement confidential.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in an IPR against Omni MedSci, finding claims 7 and 10‑14 of the ’299 patent unpatentable for obviousness over Lisogurski, Carlson, Mannheimer, and Park references.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple has filed an IPR petition asserting that Omni MedSci’s ’484 wearable health‑monitoring patent is wholly obvious over a combination of five prior‑art references. The petition seeks institution of the review and a finding that all 23 claims are unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
The PTAB held that Samsung’s challenge to Omni MedSci’s wearable physiological monitoring patent succeeded on 12 of the 23 claims, finding them obvious over prior‑art references such as Lisogurski, Carlson, Tran, Isaacson and Valencell‑093. The remaining claims were not shown unpatentable.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s ‘533 patent resulted in all challenged claims being found unpatentable. The Board held that the claims were obvious over prior‑art references Lisogurski, Carlson, and Mannheimer.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s wearable physiological‑monitoring patent was declared entirely unpatentable after Samsung’s PTAB challenge, with the Board finding the claims obvious over a combination of prior‑art references covering optical sensors, pulse‑rate modulation, spaced emitters, and reflective surfaces.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple’s IPR against Omni MedSci’s wearable health monitoring patent concluded with the Board finding all 23 claims unpatentable for obviousness. The decision affirmed the claim construction of “identify an object” and rejected the need for further briefing.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple, on behalf of Samsung, filed an IPR petition challenging Omni MedSci’s ’533 patent covering wearable optical health monitors. The petition asserts that the claims are obvious over prior art (Lisogurski, Carlson, Mannheimer) and seeks institution of the review.
SAMSUNG ELECTRONICS CO., LTD. et al. v.OMNI MEDSCI, INC.
Apple prevailed in IPR2020‑00175, with the PTAB finding all six challenged claims of the ’299 patent unpatentable as obvious over Lisogurski, Carlson, Mannheimer and Park references.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.